BioAtla, Inc. (BCAB)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Revenue from collaborative arrangement, excluding revenue from contract with customer | - | 11 | ||
| Research and development expense | 13.684 | 16.395 | ||
| General and administrative expense | 4.963 | 5.875 | ||
| Total operating expenses | 18.647 | 22.27 | ||
| Loss from operations | -18.647 | -11.27 | ||
| Other income | - | -0.008 | ||
| Interest income | 0.233 | 0.692 | ||
| Gain (loss) on warrant liability | -0.297 | - | ||
| Total other income (loss) | -0.064 | 0.684 | ||
| Net loss and comprehensive loss | -18.711 | -10.586 | ||
| Net loss per common share, basic | -0.32 | -0.22 | ||
| Net loss per common share, diluted | -0.32 | -0.22 | ||
| Weighted-average shares of common stock outstanding, basic | 58,504,396 | 48,335,847 | ||
| Weighted-average shares of common stock outstanding, diluted | 58,504,396 | 48,335,847 | ||